Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348718 | 0.87 | MEN1 (0.53) | MEN1KMT2AMAPTRAB9ATRPV1 | |
| SCHEMBL4359810 | 0.84 | MEN1 (0.56) | MEN1KMT2AMAPTRAB9ANPSR1 | |
| SCHEMBL4353169 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2AMAPTRAB9ALMNA | |
| SCHEMBL15786320 | 0.82 | P2RY1 (0.46) | P2RY1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL4343768 | 0.81 | MAPT (0.49) | MEN1KMT2AMAPTRAB9ALMNA | |
| SCHEMBL12500110 | 0.81 | P2RY1 (0.66) | P2RY1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL4345888 | 0.80 | P2RY1 (0.56) | P2RY1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL6416431 | 0.79 | GPR35 (0.44) | MEN1KMT2AMAPTRAB9ATRPV1 | |
| SCHEMBL14563706 | 0.79 | KMT2A (0.40) | MEN1KMT2ARAB9ATRPV1POLB | |
| SCHEMBL4355634 | 0.79 | MAPT (0.56) | MEN1KMT2AMAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | claimed |
| EP-1402887-A1 | New compounds for the inhibition of undesired cell proliferation and use thereof | Jerini AG (DE) | 2004-03-31 | — | — | EP | claimed |
| EP-1402888-A1 | The use of substituted carbocyclic compounds as rotamases inhibitors | Jerini AG (DE) | 2004-03-31 | — | — | EP | claimed |
| US-11583509-B2 | Compound for treating cancer and diabetes | CITY OF HOPE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11583509-B2 | Compound for treating cancer and diabetes | CITY OF HOPE (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220023240-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | CITY OF HOPE | 2022-01-27 | — | — | US | disclosed |
| US-20220023240-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | CITY OF HOPE | 2022-01-27 | — | — | US | disclosed |
| US-10588854-B2 | Polymer implants for treatment of metabolic disorders | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190000749-A1 | Polymer Implants for Treatment of Metabolic Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-03 | — | — | US | disclosed |
| US-10092508-B2 | Polymer implants for treatment of metabolic disorders | UNIVERSITY OF SOUTH CAROLINA (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170367974-A1 | Polymer Implants For Treatment Of Metabolic Disorders | UNIVERSITY OF SOUTH CAROLINA | 2017-12-28 | — | — | US | disclosed |
| US-9808434-B2 | Compound for treating cancer and diabetes | CITY OF HOPE (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808434-B2 | Compound for treating cancer and diabetes | CITY OF HOPE (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160354327-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | CITY OF HOPE | 2016-12-08 | — | — | US | disclosed |
| US-20160354327-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | CITY OF HOPE | 2016-12-08 | — | — | US | disclosed |
| WO-2012103523-A2 | NOVEL MODULATORS OF DEVELOPMENT OF ADIPOCYTE AND CANCER CELLS | RAHBAR SAMUEL (US) | 2012-08-02 | — | — | WO | disclosed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | P2RY1 3208/4885MEN1 2168/4885KMT2A 2096/4885 |
| US-20170367974-A1 | Polymer Implants For Treatment Of Metabolic Disorders | LRBA, FABP4, APMAP | P2RY1 3152/4885MEN1 3428/4885KMT2A 1073/4885 |
| US-10588854-B2 | Polymer implants for treatment of metabolic disorders | LRBA, FABP4, APMAP | P2RY1 3152/4885MEN1 3428/4885KMT2A 1073/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | P2RY1 3254/4885MEN1 3901/4885KMT2A 1254/4885 |
| US-20220023240-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | TP53, VHL, SLC2A4 | P2RY1 4063/4885MEN1 1206/4885KMT2A 1538/4885 |
| US-11583509-B2 | Compound for treating cancer and diabetes | TP53, VHL, SLC2A4 | P2RY1 4063/4885MEN1 1206/4885KMT2A 1538/4885 |
| US-10092508-B2 | Polymer implants for treatment of metabolic disorders | LRBA, FABP4, APMAP | P2RY1 3152/4885MEN1 3428/4885KMT2A 1073/4885 |
| US-20160354327-A1 | COMPOUND FOR TREATING CANCER AND DIABETES | TP53, VHL, SLC2A4 | P2RY1 4063/4885MEN1 1206/4885KMT2A 1538/4885 |
| US-20190000749-A1 | Polymer Implants for Treatment of Metabolic Disorders | LRBA, FABP4, APMAP | P2RY1 3152/4885MEN1 3428/4885KMT2A 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.